bs-13337R [Primary Antibody]
GFI1/ZNF163 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: GFI1/ZNF163

Immunogen Range: 301-400/422


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 2672

Source: KLH conjugated synthetic peptide derived from human GFI1/ZNF163

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

Growth factor independent 1 (Gfi-1) is a transcriptional repressor that specifically binds to the DNA consensus sequence TAAATCAC(A/T)GCA. The carboxy-terminus of Gfi-1 contains six C2H2-type zinc finger motifs, and zinc fingers 3, 4 and 5 are required for the binding of Gfi-1 to its DNA binding site. Gfi-1 also contains a 20 amino acid SNAG domain which mediates transcriptional repression. It represses Bax at the mRNA and protein levels, resulting in the inhibition of cell death. Gfi1 is expressed outside the lymphoid system in granulocytes and activated macrophages. Gfi-1B, a related protein, is a transcriptional repressor primarily expressed in bone marrow and spleen. Gfi-1B is a direct repressor of the p21 promoter and the Socs 1 and 3 promoters. The genes encoding human Gfi-1 and Gfi-1B map to chromosome 1p22 and 9q34.3, respectively.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)
ICC(1:100-500)

Predicted Molecular Weight: 45


Cross Reactive Species: Mouse
Rat
Xenopus laevis

Predicted Cross Reactive Species: Human
Dog
Sheep
Pig
Horse
Rabbit

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Lane 1: Mouse Lung lysates; Lane 2: Mouse Lymph node lysates probed with GFI1/ZNF163 Polyclonal Antibody, Unconjugated (bs-13337R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.